187 related articles for article (PubMed ID: 33948072)
1. Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis.
Barnes A; Hofmann D; Hall LA; Klebe S; Mountifield R
Ann Gastroenterol; 2021; 34(3):447-448. PubMed ID: 33948072
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.
Lieb S; Heni M; Rauschenberg S; Lange K; Feisthammel J; Bläker H; Wiegand J
Z Gastroenterol; 2023 Nov; 61(11):1500-1503. PubMed ID: 36736346
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review.
Tolaymat S; Sharma K; Kagzi Y; Sriwastava S
Mult Scler Relat Disord; 2023 Jul; 75():104763. PubMed ID: 37229799
[TBL] [Abstract][Full Text] [Related]
4. Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis.
Duarte DB; Silva AMD; Freitas C; Cardoso H
Endocr Regul; 2021 Sep; 55(3):169-173. PubMed ID: 34523298
[No Abstract] [Full Text] [Related]
5. Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Gingele S; Jacobus TL; Konen FF; Hümmert MW; Sühs KW; Schwenkenbecher P; Ahlbrecht J; Möhn N; Müschen LH; Bönig L; Alvermann S; Schmidt RE; Stangel M; Jacobs R; Skripuletz T
Cells; 2018 Dec; 8(1):. PubMed ID: 30597851
[TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
9. Ocrelizumab for the treatment of multiple sclerosis.
Bigaut K; De Seze J; Collongues N
Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
[TBL] [Abstract][Full Text] [Related]
10. Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab.
Haberli N; Coban H; Padam C; Montezuma-Rusca JM; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Feb; 48():102731. PubMed ID: 33450528
[TBL] [Abstract][Full Text] [Related]
11. [Ocrelizumab for treatment of multiple sclerosis].
Graf J; Albrecht P; Goebels N; Aktas O; Hartung HP
Nervenarzt; 2020 Aug; 91(8):722-734. PubMed ID: 32524163
[TBL] [Abstract][Full Text] [Related]
12. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.
Torres JB; Roodselaar J; Sealey M; Ziehn M; Bigaud M; Kneuer R; Leppert D; Weckbecker G; Cornelissen B; Anthony DC
Front Immunol; 2022; 13():814064. PubMed ID: 35967378
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe.
Aun MV; Freua F; Marussi VHR; Giavina-Bianchi P
Front Immunol; 2022; 13():840238. PubMed ID: 35222433
[TBL] [Abstract][Full Text] [Related]
14. B cell depletion in the treatment of multiple sclerosis.
Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
[TBL] [Abstract][Full Text] [Related]
15. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
16. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
Pukoli D; Vécsei L
Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
[TBL] [Abstract][Full Text] [Related]
17. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Auer M; Bsteh G; Hegen H; Wurth S; Zinganell A; Berger T; Deisenhammer F; Pauli FD
Mult Scler Relat Disord; 2020 Aug; 43():102155. PubMed ID: 32470856
[TBL] [Abstract][Full Text] [Related]
18. Crohn's disease induced by ocrelizumab in a patient with multiple sclerosis.
Carballo-Folgoso L; Celada-Sendino M; Castaño-García A; Oliva Nacarino P; Morales Del Burgo P; Pérez-Martínez I; de Francisco R; Riestra S
Rev Esp Enferm Dig; 2022 Dec; 114(12):766-767. PubMed ID: 36177822
[TBL] [Abstract][Full Text] [Related]
19. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
20. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab.
Alba Suárez EM; Tallón Barranco A; Puertas Muñoz I; Chamorro Hernández B; Robles Marhuenda Á
Neurologia (Engl Ed); 2023 Sep; 38(7):463-466. PubMed ID: 37659836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
